To the Editor: Two years ago, we reported that the incorporationof thalidomide into high-dose therapy for myeloma increasedthe frequency of complete remission but not the duration ofremission and extended event-free survival but not overall survival.1We now report that after a median follow-up of 8 years, 399patients remain alive and 286 are event-free, for median durationsof 9 years and 5 years, respectively. Although the overall differencein the 8-year survival estimates of 56% for 323 patients whowere randomly assigned to the thalidomide group and 45% for345 patients in the control group was not . . . [Full Text of this Article]
Barlogie, B., Shaughnessy, J. D. Jr., Crowley, J.
(2008). Retraction: Barlogie et al. Duration of Survival in Patients with Myeloma Treated with Thalidomide. N Engl J Med 2008;359:210-2.. NEJM
359: 1410-1410
[Full Text]
van Rhee, F., Dhodapkar, M., Shaughnessy, J. D. Jr, Anaissie, E., Siegel, D., Hoering, A., Zeldis, J., Jenkins, B., Singhal, S., Mehta, J., Crowley, J., Jagannath, S., Barlogie, B.
(2008). First thalidomide clinical trial in multiple myeloma: a decade. Blood
112: 1035-1038
[Abstract][Full Text]
Previous
